HEALTH PROFESSIONAL · SOURCE READING

Treatment Option Overview for Childhood Craniopharyngioma

Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 26, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Treatments for pediatric craniopharyngiomas have traditionally included maximal safe surgical resection and radiation therapy to treat residual tumor. Additionally, intracystic therapies such as radioactive phosphorus P 32, bleomycin, and interferon-alpha have been used. Evidence has demonstrated that conservative surgical approaches lead to better neuroendocrine and quality-of-life outcomes in patients.[1,2] Additionally, as the biological understanding of molecular and inflammatory drivers of these tumors have been identified, targeted therapies are now being studied.

Source links and citations

Table 1 describes the treatment options for newly diagnosed and recurrent childhood craniopharyngioma.

Source links and citations

Table 1

Table 1. Treatment Options for Childhood Craniopharyngioma
Treatment Group	Treatment Options
Newly diagnosed childhood craniopharyngioma	Complete resection with or without radiation therapy
	Subtotal resection with radiation therapy
	Primary cyst drainage with or without radiation therapy
	Intracystic therapy
Progressive or recurrent childhood craniopharyngioma	Surgery
	Radiation therapy, including radiosurgery
	Intracystic therapy (intracavitary instillation of radioactive phosphorus P 32 or bleomycin for those with cystic recurrences, where these agents are available)
	Systemic and targeted therapy
	Observation

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice